AROG Pharmaceuticals and Mentrik Biotech
Arog Pharmaceuticals, LLC is developing CRENOLANIB, an orally bioavailable, mutant specific type I inhibitor of receptor kinases FLT3, PDGFRa, and PDGFRb. Crenolanib is currently in phase III development in AML and GIST. Mentrik Biotech, LLC is developing OCARATUZUMAB, an Fc- and Fab-engineered humanized anti-CD20 monoclonal antibody, in B-cell malignancies. Phase II trials in follicular lymphoma have already been conducted in US and Japan with a Phase I trial in rheumatoid arthritis initiated.